Hemodialysis-associated cardiomyopathy: A newly defined disease entity

Seminars in Dialysis

Volumn 27, Issue 2, 2014, Pages 87-97

  McIntyre, Christopher W ^a,b   Odudu, Aghogho ^a,b  

^a ROYAL DERBY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOMYOPATHIES; DISEASE COURSE; HUMAN; RENAL REPLACEMENT THERAPY;

CARDIOMYOPATHIES; DISEASE PROGRESSION; HUMANS; RENAL DIALYSIS;

EID: 84895078609     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/sdi.12197     Document Type: Article

References (111)

1. Sarnak MJ, Levey AS: Epidemiology of cardiac disease in dialysis patients. Semin Dial 12:69-76, 1999.
2. Gross ML, Ritz E: Hypertrophy and fibrosis in the cardiomyopathy of uremia-beyond coronary heart disease. Semin Dial 21:308-318, 2008
3. McIntyre CW: Recurrent circulatory stress: the dark side of dialysis. Semin Dial 23(5):449-451, 2010
4. McIntyre CW, Burton JO, Selby NM, Leccisotti L, Korsheed S, Baker CSR, Camici PG: Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol 3(1):19-26, 2008
5. Burton JO, Jefferies HJ, Selby NM, McIntyre CW: Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol 4(5):914-920, 2009.
6. Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebede M, Salama L, Lambrey G, Witko-Sarsat V, Drueke TB, Lacour B, Thevenin M: Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 16:335-340, 2001
7. Bansal S, Siddarth M, Chawla D, Banerjee BD, Madhu SV, Tripathi AK: Advanced glycation end products enhance reactive oxygen and nitrogen species generation in neutrophils in vitro. Mol Cell Biochem 361(1-2):289-296, 2012
8. Basta G, Schmidt AM, De Caterina R: Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63(4):582-592, 2004
9. Silver J, Rodriguez M, Slatopolsky E: FGF23 and PTH-double agents at the heart of CKD. Nephrol Dial Transplant 27(5):1715-1720, 2012 Central PMCID: PMC3471546.
10. van Ballegooijen AJ, Reinders I, Visser M, Brouwer IA: Parathyroid hormone and cardiovascular disease events: a systematic review and meta-analysis of prospective studies. Am Heart J 165(5):655-664, 2013.
11. Sigrist MK, Levin A, Er L, McIntyre CW: Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrol Dial Transplant 24(10):3157-3162, 2009
12. Elkareh J, Kennedy DJ, Yashaswi B, Vetteth S, Shidyak A, Kim EG, Smaili S, Periyasamy SM, Hariri IM, Fedorova L, Liu J, Wu L, Kahaleh MB, Xie Z, Malhotra D, Fedorova OV, Kashkin VA, Bagrov AY, Shapiro JI: Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy. Hypertension 49:215-224, 2007
13. Kennedy DJ, Vetteth S, Periyasamy SM, Kanj M, Fedorova L, Khouri S, Kahaleh MB, Xie Z, Malhotra D, Kolodkin NI, Lakatta EG, Fedorova OV, Bagrov AY, Shapiro JI: Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension 47:488-495, 2006
14. Colombo PC, Ganda A, Lin J, Onat D, Harxhi A, Iyasere JE, Uriel N, Cotter G: Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev 17(2):177-190, 2012
15. Hutchison CA, Landgren O: Polyclonal immunoglobulin free light chains as a potential biomarker of immune stimulation and inflammation. Clin Chem 57(10):1387-1389, 2011
16. Haynes R, Hutchison CA, Emberson J, Dasgupta T, Wheeler DC, Townend JN, Landray MJ, Cockwell P: Serum free light chains and the risk of ESRD and death in CKD. Clin J Am Soc Nephrol 6(12):2829-2837, 2011
17. Assi LK, McIntyre NJ, Hutchison CA, McIntyre CW, Cockwell P, Taal MW: High Serum polyclonal free light chain levels are independently associated with increased mortality in stage 3 CKD. Presented at ASN Conference, San Diego, CA, November 4, 2012
18. Lew WY, Bayna E, Molle ED, Dalton ND, Lai NC, Bhargava V, Mendiola V, Clopton P, Tang T: Recurrent exposure to subclinical lipopolysaccharide increases mortality and induces cardiac fibrosis in mice. PLoS ONE 8(4):e61057, 2013
19. Charalambous BM, Stephens RC, Feavers IM, Montgomery HE: Role of bacterial endotoxin in chronic heart failure: the gut of the matter. Shock 28(1):15-23, 2007
20. Krack A, Sharma R, Figulla HR, Anker SD: The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J 26(22):2368-2374, 2005
21. Anker SD, Egerer KR, Volk HD, Kox WJ, Poole-Wilson PA, Coats AJ: Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 79(10):1426-1430, 1997
22. Feng SY, Samarasinghe T, Phillips DJ, Alexiou T, Hollis JH, Yu VY, Walker AM: Acute and chronic effects of endotoxin on cerebral circulation in lambs. Am J Physiol Regul Integr Comp Physiol 298:R760-R766, 2010
23. McIntyre CW, Harrison LE, Eldehni MT, Jefferies HJ, Szeto CC, John SG, Sigrist MK, Burton JO, Hothi D, Korsheed S, Owen PJ, Lai KB, Li PK: Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol 6:133-141, 2011
24. Harrison LEA, Jefferies HJ, Burton JO, Szeto CC, Li PK, Virk B, Schiller B, Moran J, McIntyre CW: Circulating endotoxaemia and frequent haemodialysis schedules. Nephron Clin Pract In press, 2014
25. Brownlee M: Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46:223-234, 1995
26. McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW: Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3. Clin J Am Soc Nephrol 6(10):2356-2363, 2011
27. Crowley LE, Johnson CP, McIntyre N, Fluck RJ, McIntyre CW, Taal MW, Leung JC: Tissue advanced glycation end product deposition after kidney transplantation. Nephron Clin Pract 124(1-2):54-59, 2013 [Epub ahead of print]
28. McIntyre NJ, Chesterton LJ, John SG, Jefferies HJ, Burton JO, Taal MW, Fluck RJ, McIntyre CW: Tissue-advanced glycation end product concentration in dialysis patients. Clin J Am Soc Nephrol 5(1):51-55, 2010
29. Thorpe SR, Baynes JW: Maillard reaction products in tissue proteins: new products and new perspectives. [Review] [25 refs]. Amino Acids 25(3-4):275-281, 2003
30. Ramasamy R, Yan SF, Herold K, Clynes R, Schmidt AM: Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Ann N Y Acad Sci 1126:7-13, 2008
31. Aronson D: Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 21(1):3-12, 2003
32. Baynes J: From life to death-the struggle between chemistry and biology during aging: the Maillard reaction as an amplifier of genomic damage. Biogerontology 1(3):235-246, 2000
33. Linden E, Cai W, He J, Xue C, Li Z, Winston J, Vlassara H, Uribarri J: Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin J Am Soc Nephrol 3(3):691-698, 2008
34. Gerrits EG, Lutgers HL, Kleefstra N, Graaff R, Groenier KH, Smit AJ, Gans RO, Bilo HJ: Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 31(3):517-521, 2008
35. Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving HH, Tarnow L, Rossing P, Stehouwer CD: Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care 34(2):442-447, 2011
36. Meerwaldt R, Lutgers HL, Links TP, Graaff R, Baynes JW, Gans RO, Smit AJ: Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 30(1):107-112, 2007
37. Meerwaldt R, Links T, Graaff R, Thorpe S, Baynes J, Hartog J, Gans R, Smit A: Simple noninvasive measurement of skin autofluorescence. Diabetologia 47(7):1324-1330, 2004
38. Meerwaldt R, Hartog J, Graaff R, Huisman R, Links T, den Hollander N, Thorpe SR, Baynes JW, Navis G, Gans RO, Smit AJ: Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 16(12):3687-3693, 2005
39. McIntyre NJ, Fluck RJ, McIntyre CW, Fakis A, Taal MW: Determinants of arterial stiffness in chronic kidney disease stage 3. PLoS ONE 8(1):e55444, 2013
40. Bleyer AJ, Hartman J, Brannon PC, Reeves-Daniel A, Satko SG, Russell G: Characteristics of sudden death in hemodialysis patients. Kidney Int 69:2268-2273, 2006
41. Kingwell BA, Waddell TK, Medley TL, Cameron JD, Dart AM: Large artery stiffness predicts ischemic threshold in patients with coronary artery disease. J Am Coll Cardiol 40:773-779, 2002
42. Stewart GA, Mark PB, Johnston N, et al.: Determinants of hypertension and left ventricular function in end stage renal failure: a pilot study using cardiovascular magnetic resonance imaging. Clin Physiol Funct Imaging 24:387-393, 2004
43. Mohi-ud-din K, Bali HK, Banerjee S, Sakhuja V, Jha V: Silent myocardial ischemia and high-grade ventricular arrhythmias in patients on maintenance hemodialysis. Ren Fail 27:171-175, 2005
44. Narula AS, Jha V, Bali HK, Sakhuja V, Sapru RP: Cardiac arrhythmias and silent myocardial ischemia during hemodialysis. Ren Fail 22:355-368, 2000.
45. Sigrist MW, Bungay P, McIntyre CW: Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Sigrist MK, Taal. Clin J Am Soc Nephrol 2(6):1241-1248, 2007 Nov
46. Ohtsuka S, Kakihana M, Watanabe H, Sugishita Y: Chronically decreased aortic distensibility causes deterioration of coronary perfusion during increased left ventricular contraction. J Am Coll Cardiol 24(5):1406-1414, 1994
47. Mullens W, Keyser JD, Droogne W: Images in cardiology. Myocardial calcification: a rare cause of diastolic dysfunction. Heart 92(2):195, 2006
48. Isotalo PA, Halil A, Green M, Tang A, Lach B, Veinot JP: Metastatic calcification of the cardiac conduction system with heart block: an under-reported entity in chronic renal failure patients. J Forensic Sci 45(6):1335-1338, 2000
49. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Brunet P: Vascular incompetence in dialysis patients-protein-bound uremic toxins and endothelial dysfunction. Semin Dial 24(3):327-337, 2011
50. Chesterton LJ, Selby NM, Burton JO, Fialova J, Chan C, McIntyre CW: Categorization of the hemodynamic response to hemodialysis: the importance of baroreflex sensitivity. Hemodial Int 14(1):18-28, 2010
51. Chesterton LJ, McIntyre CW: The assessment of baroreflex sensitivity in patients with chronic kidney disease: implications for vasomotor instability. Curr Opin Nephrol Hypertens 14(6):586-591, 2005
52. Morris ST, McMurray JJ, Spiers A, Jardine AG: Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int 60(3):1077-1082, 2001
53. Glassock RJ, Pecoits-Filho R, Barberato SH: Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol 4(Suppl 1):S79-S91, 2009
54. Stella P, Manunta P, Mallamaci F, Melandri M, Spotti D, Tripepi G, Hamlyn JM, Malatino LS, Bianchi G, Zoccali C: Endogenous ouabain and cardiomyopathy in dialysis patients. J Intern Med 263(3):274-280, 2008
55. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, de Filippi C, Wolf M: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119(19):2545-2552, 2009
56. Bagrov AY, Fedorova OV: Cardenolide and bufadienolide ligands of the sodium pump. How they work together in NaCl sensitive hypertension. Front Biosci 10:2250-2256, 2005
57. Chan CT, Floras JS, Miller JA, Richardson RM, Pierratos A: Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 61:2235-2239, 2002
58. Chan CT, Arab S, Carasso S, Moravsky G, Li GH, Liu PP, Rakowski H: Impact of frequent nocturnal hemodialysis on myocardial mechanics and cardiomyocyte gene expression. Circ Cardiovasc Imaging 5(4):474-480, 2012
59. McIntyre CW, Odudu A, Eldehni MT: Cardiac assessment in chronic kidney disease. Curr Opin Nephrol Hypertens 18(6):501-506, 2009
60. Palmiero P, Maiello M, Nanda NC: Is echo-determined left ventricular geometry associated with ventricular filling and midwall shortening in hypertensive ventricular hypertrophy? Echocardiography 25(1):20-26, 2008
61. Liu YW, Su CT, Sung JM, Wang SPH, Su YR, Yang CS, Tsai LM, Chen JH, Tsai W-C: Association of left ventricular longitudinal strain with mortality among stable hemodialysis patients with preserved left ventricular ejection fraction. Clin J Am Soc Nephrol 8(9):1564-1574, 2013
62. Liu YW, Tsai WC, Su CT, Lin CC, Chen JH: Evidence of left ventricular systolic dysfunction detected by automated function imaging in patients with heart failure and preserved left ventricular ejection fraction. J Cardiac Fail 15(9):782-789, 2009
63. Mignot A, Donal E, Zaroui A, Reant P, Salem A, Hamon C, Monzy S, Roudaut R, Habib G, Lafitte S: Global longitudinal strain as a major predictor of cardiac events in patients with depressed left ventricular function: a multicenter study. J Am Soc Echocardiogr 23(10):1019-1024, 2010
64. Stanton T, Leano R, Marwick TH: Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring. Circ Cardiovasc Imaging 2(5):356-364, 2009
65. Rakhit DJ, Zhang XH, Leano R, Armstrong KA, Isbel NM, Marwick TH: Prognostic role of subclinical left ventricular abnormalities and impact of transplantation in chronic kidney disease. Am Heart J 153(4):656-664, 2007
66. Huanga S-HS, Crowley LE, Jefferies HJ, Eldehni MT, Odudu A, McIntyre CW: Hemodialysis induced cardiac stunning: impact on segmental and global longitudinal myocardial strain. Presented at ASN Conference, Atlanta, GA, November 8, 2013
67. Odudu A, Eldheni MT, McCann GP, McIntyre CW. Cardiac magnetic resonance tagging identifies systolic abnormalities in the majority of incident haemodialysis patients. Presented as conference abstract, Renal Association Bournemouth, UK, May 2013
68. Mark PB, Johnston N, Groenning BA, Foster JE, Blyth KG, Martin TN, Steedman T, Dargie HJ, Jardine AG: Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 69(10):1839-1845, 2006
69. Stewart GA, Mark PB, Johnston N, Foster JE, Cowan M, Rodger RS, Dargie HJ, Jardine AG: Determinants of hypertension and left ventricular function in end stage renal failure: a pilot study using cardiovascular magnetic resonance imaging. Clin Physiol Funct Imaging 24(6):387-393, 2004
70. Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, Bonanno G, Fatuzzo P, Rapisarda F, Seminara G, Stancanelli B, Bellanuova I, Cataliotti A, Malatino LS: Diagnostic value of troponin T for alterations in left ventricular mass and function in dialysis patients. Kidney Int 62(5):1884-1890, 2002
71. Liu Y-W, Su C-T, Chou C-C, Wang SPH, Yang C-S, Huang Y-Y, Tsai L-M, Chen J-H, Tsai W-C: Association of Subtle Left Ventricular Systolic Dysfunction with Elevated Cardiac Troponin T in Asymptomatic Hemodialysis Patients with Preserved Left Ventricular Ejection Fraction. Acta Cardiol Sin 28:95-102, 2012
72. Iwabuchi Y, Ogawa T, Inoue T, Otsuka K, Nitta K: Elevated E/E' predicts cardiovascular events in hemodialysis patients with preserved systolic function. Intern Med 51:155-160, 2012
73. Torrent-Guasp F, Ballester M, Buckberg GD, Carreras F, Flotats A, Carrio I, Ferreira A, Samuels LE, Narula J: Spatial orientation of the ventricular muscle band: physiologic contribution and surgical implications. J Thorac Cardiovasc Surg 122:389-392, 2001
74. Davies JE, Whinnett ZI, Francis DP, Manisty CH, Aguado-Sierra J, Willson K, Foale RA, Malik IS, Hughes AD, Parker KH, Mayet J: Evidence of a dominant backward-propagating "suction" wave responsible for diastolic coronary filling in humans, attenuated in left ventricular hypertrophy. Circulation 113:1768-1778, 2006
75. Ie EH, Zietse R: Evaluation of cardiac function in the dialysis patient-a primer for the non-expert. Nephrol Dial Transplant 21:1474-1481, 2006
76. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE: Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int 54(5):1720-1725, 1998
77. Bluemke DA, Kronmal RA, Lima JAC, Liu K, Olson J, Burke GL, Folsom AR: The relationship of left ventricular mass and geometry to incident cardiovascular events. J Am Coll Cardiol 52(25):2148-2155, 2008
78. Otterstad JE, Froeland G, St. John Sutton M, Holme I: Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function. Eur Heart J 18(3):507-513, 1997
79. Gottdiener JS, Livengood SV, Meyer PS, Chase GA: Should echocardiography be performed to assess effects of antihypertensive therapy? Test-retest reliability of echocardiography for measurement of left ventricular mass and function. J Am Coll Cardiol 25(2):424-430, 1995
80. Mark PB, Patel RK, Jardine AG: Are we overestimating left ventricular abnormalities in end-stage renal disease? Nephrol Dial Transplant 22(7):1815-1819, 2007
81. Breidthardt T, Burton JO, Odudu A, Eldehni MT, Jefferies H, McIntyre CW: N-terminal Pro-B-type natriuretic peptide and its correlation to haemodialysis-induced myocardial stunning. Nephron Clin Pract 123(1-2):118-122, 2013
82. Thygesen K, Alpert JS, White HD: Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction: Universal definition of myocardial infarction. Circulation 116:2634-2653, 2007.
83. Apple FS, Wu AH, Jaffe AS: European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. Am Heart J 144:981-986, 2002
84. Eggers KM, Oldgren J, Nordenskjold A, Lindahl B: Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. Am Heart J 148:574-581, 2004
85. Hochholzer W, Morrow DA, Giugliano RP: Novel biomarkers in cardiovascular disease: update. Am Heart J 160:583-594, 2010.
86. Morrow DA, Antman EM, Tanasijevic M, Rifai N, de Lemos JA, McCabe CH, Cannon CP, Braunwald E: Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol 36:1812-1817, 2000
87. Ooi DS, House AA: Cardiac troponin T in hemodialyzed patients. Clin Chem 44:1410-1416, 1998
88. Ishii J, Nomura M, Okuma T, Minagawa T, Naruse H, Mori Y, Ishikawa T, Kurokawa H, Hirano T, Kondo T, Nagamura Y, Ezaki K, Hishida H: Risk stratification using serum concentrations of cardiac troponin T in patients with end-stage renal disease on chronic maintenance dialysis. Clin Chim Acta 312:69-79, 2001
89. Conway B, McLaughlin M, Sharpe P, Harty J: Use of cardiac troponin T in diagnosis and prognosis of cardiac events in patients on chronic haemodialysis. Nephrol Dial Transplant 20:2759-2764, 2005
90. Selby NM, Lambie SH, Camici PG, Baker CS, McIntyre CW: Occurrence of regional left ventricular dysfunction in patients undergoing standard and biofeedback dialysis. Am J Kidney Dis 47:830-841, 2006
91. Selby NM, Burton JO, Chesterton LJ, McIntyre CW: Dialysis-induced regional left ventricular dysfunction is ameliorated by cooling the dialysate. Clin J Am Soc Nephrol 1:1216-1225, 2006
92. Jefferies HJ, Virk B, Moran J, Schiller B, McIntyre CW. Frequent haemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning). Clin J Am Soc Nephrol 6(6):1326-32, 2011
93. Braunwald E, Kloner R: The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 66:1146-1149, 1982
94. Barnes E, Dutka DP, Khan M, Camici PG, Hall RJ: Effect of repeated episodes of reversible myocardial ischemia on myocardial blood flow and function in humans. Am J Physiol Heart Circ Physiol 282:H1603-H1608, 2002
95. Braunwald E, Rutherford JD: Reversible ischemic left ventricular dysfunction. evidence for the "hibernating myocardium". J Am Coll Cardiol 8(6):1467-1470, 1986
96. McIntyre CW: Effects of hemodialysis on cardiac function. Kidney Int 76(4):371-375, 2009
97. McIntyre CW: Haemodialysis-induced myocardial stunning in chronic kidney disease - a new aspect of cardiovascular disease. Blood Purif 29(2):105-110, 2010
98. Selby NM, McIntyre CW: The acute cardiac effects of dialysis. Semin Dial 20(3):220-228, 2007
99. Burton JO, Korsheed S, Grundy BJ, McIntyre CW: Hemodialysis-induced left ventricular dysfunction is associated with an increase in ventricular arrhythmias. Ren Fail 30(7):701-709, 2008
100. Dasselaar JJ, Slart RH, Knip M, Pruim J, Tio RA, McIntyre CW, de Jong PE, Franssen CF: Haemodialysis is associated with a pronounced fall in myocardial perfusion. Nephrol Dial Transplant 24(2):604-610, 2009
101. Burton JO, Jefferies HJ, Selby NM, McIntyre CW: Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clin J Am Soc Nephrol 4(12):1925-1931, 2009
102. Jefferies HJ, Virk B, Schiller B, Moran J, McIntyre CW: Frequent hemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning). Clin J Am Soc Nephrol 6(6):1326-1332, 2011
103. Assa S, Hummel YM, Voors AA, Kuipers J, Groen H, de Jong PE, Westerhuis R, Franssen CF: Changes in left ventricular diastolic function during haemodialysis sessions. Am J Kidney Dis 62(3):549-556, 2013
104. Pecoits-Filho R, Bucharles S, Barberato SH: Diastolic heart failure in dialysis patients: mechanisms, diagnostic approach, and treatment. Semin Dial 25:35-41, 2012
105. Selby NM, Burton JO, Chesterton LJ, McIntyre CW: Dialysis-induced regional left ventricular dysfunction is ameliorated by cooling the dialysate. Clin J Am Soc Nephrol 1(6):1216-1225, 2006
106. Selby NM, Lambie SH, Camici PG, Baker CS, McIntyre CW: Occurrence of regional left ventricular dysfunction in patients undergoing standard and biofeedback dialysis. Am J Kidney Dis 47(5):830-841, 2006
107. Selby NM, McIntyre CW: How should dialysis fluid be individualized for the chronic hemodialysis patient? Temperature Semin Dial 21(3):229-231, 2008
108. Chesterton LJ, Selby NM, Burton JO, McIntyre CW: Cool dialysate reduces asymptomatic intradialytic hypotension and increases baroreflex variability. Hemodial Int 13(2):189-196, 2009
109. Jefferies HJ, Burton JO, McIntyre CW: Individualised dialysate temperature improves intradialytic haemodynamics and abrogates haemodialysis-induced myocardial stunning, without compromising tolerability. Blood Purif 32(1):63-68, 2011
110. Odudu A, Eldehni MT, Fakis A, McIntyre CW: Rationale and design of a multi-centre randomised controlled trial of individualised cooled dialysate to prevent left ventricular systolic dysfunction in haemodialysis patients. BMC Nephrol 21(13):45, 2012
111. Odudu A, Eldehni MT, McCann GP, McIntyre CW: Prospective randomized controlled trial of individualized dialysate cooling to provide brain and cardiac protection in hemodialysis patients. Presented at ASN Conference, Atlanta, GA, November 8, 2013